Knockdown of NANOG enhances chemosensitivity of liver cancer cells to doxorubicin by reducing MDR1 expression

International Journal of Oncology

Volumn 45, Issue 6, 2014, Pages 2034-2040

  Zhou, Jia Jia ^a   Deng, Xiao Geng ^a   He, Xiao Yu ^b   Zhou, Yu ^a   Yu, Min ^a   Gao, Wen Chao ^a   Zeng, Bing ^a   Zhou, Quan Bo ^a   Li, Zhi Hua ^a   Chen, Ru Fu ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b Guangdong Provincial Institute of Sports Science   (China)

Author keywords

Chemosensitivity; Doxorubicin; Hepatocellular carcinoma; Multidrug resistance gene 1; NANOG

Indexed keywords

DOXORUBICIN; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR NANOG; ABCB1 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; HOMEODOMAIN PROTEIN; MULTIDRUG RESISTANCE PROTEIN; NANOG PROTEIN, HUMAN;

ARTICLE; CELL MIGRATION; CELL VIABILITY; CHEMOSENSITIVITY; COLONY FORMATION; CONTROLLED STUDY; DOWN REGULATION; GENE SILENCING; HEPG2 CELL LINE; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE; CANCER CELL; DRUG MECHANISM; GENETIC TRANSFECTION; LIVER CANCER; CELL MOTION; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; LIVER NEOPLASMS; METABOLISM; PATHOLOGY;

ANTINEOPLASTIC AGENTS; CELL MOVEMENT; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HEP G2 CELLS; HOMEODOMAIN PROTEINS; HUMANS; LIVER NEOPLASMS; P-GLYCOPROTEINS;

EID: 84899582429     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2347     Document Type: Article

References (32)

1. Okuda K: Hepatocellular carcinoma. J Hepatol 32: 225-237, 2000.
2. Parkin DM, Bray F, Ferlay J and Pisani P: Estimating the world cancer burden: Globocan 2000. Int J Cancer 94: 153-156, 2001.
3. Lee JH, Chung YH, Kim JA, et al: Genetic predisposition of hand-foot skin reaction after sorafenib therapy in patients with hepatocellular carcinoma. Cancer 119: 136-142, 2013.
4. Sauer G, Kafka A, Grundmann R, Kreienberg R, Zeillinger R and Deissler H: Basal expression of the multidrug resistance gene 1 (MDR-1) is associated with the TT genotype at the polymorphic site C3435T in mammary and ovarian carcinoma cell lines. Cancer Lett 185: 79-85, 2002.
5. Ling V: Multidrug resistance and P-glycoprotein expression. Ann NY Acad Sci 507: 7-8, 1987.
6. Roninson IB, Chin JE, Choi KG, et al: Isolation of human mdr DNA sequences amplified in multidrug-resistant KB carcinoma cells. Proc Natl Acad Sci USA 83: 4538-4542, 1986.
7. Chambers I, Colby D, Robertson M, Nichols J, Lee S, Tweedie S and Smith A: Functional expression cloning of Nanog, a pluripotency sustaining factor in embryonic stem cells. Cell 113: 643-655, 2003.
8. Mitsui K, Tokuzawa Y, Itoh H, et al: The homeoprotein Nanog is required for maintenance of pluripotency in mouse epiblast and ES cells. Cell 113: 631-642, 2003.
9. Freberg CT, Dahl JA, Timoskainen S and Collas P: Epigenetic reprogramming of OCT4 and NANOG regulatory regions by embryonal carcinoma cell extract. Mol Biol Cell 18: 1543-1553, 2007.
10. Ben-Porath I, Thomson MW, Carey VJ, Ge R, Bell GW, Regev A and Weinberg RA: An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet 40: 499-507, 2008.
11. Gu G, Yuan J, Wills M and Kasper S: Prostate cancer cells with stem cell characteristics reconstitute the original human tumor in vivo. Cancer Res 67: 4807-4815, 2007.
12. Zbinden M, Duquet A, Lorente-Trigos A, Ngwabyt SN, Borges I and Ruiz i Altaba A: NANOG regulates glioma stem cells and is essential in vivo acting in a cross-functional network with GLI1 and p53. EMBO J 29: 2659-2674, 2010.
13. Seigel GM, Hackam AS, Ganguly A, Mandell LM and Gonzalez-Fernandez F: Human embryonic and neuronal stem cell markers in retinoblastoma. Mol Vis 13: 823-832, 2007.
14. Meng HM, Zheng P, Wang XY, et al: Overexpression of nanog predicts tumor progression and poor prognosis in colorectal cancer. Cancer Biol Ther 9: 295-302, 2010.
15. Jeter CR, Badeaux M, Choy G, et al: Functional evidence that the self-renewal gene NANOG regulates human tumor development. Stem Cells 27: 993-1005, 2009.
16. Jeter CR, Liu B, Liu X, et al: NANOG promotes cancer stem cell characteristics and prostate cancer resistance to androgen deprivation. Oncogene 30: 3833-3845, 2011.
17. Du Y, Shi L, Wang T, Liu Z and Wang Z: Nanog siRNA plus Cisplatin may enhance the sensitivity of chemotherapy in esophageal cancer. J Cancer Res Clin Oncol 138: 1759-1767, 2012.
18. Dalerba P, Cho RW and Clarke MF: Cancer stem cells: models and concepts. Annu Rev Med 58: 267-284, 2007.
19. Dalerba P and Clarke MF: Cancer stem cells and tumor metastasis: first steps into uncharted territory. Cell Stem Cell 1: 241-242, 2007.
20. Yu F, Yao H, Zhu P, et al: let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 131: 1109-1123, 2007.
21. Xu XL, Xing BC, Han HB, et al: The properties of tumorinitiating cells from a hepatocellular carcinoma patient's primary and recurrent tumor. Carcinogenesis 31: 167-174, 2010.
22. Al-Hajj M: Cancer stem cells and oncology therapeutics. Curr Opin Oncol 19: 61-64, 2007.
23. Boyer LA, Lee TI, Cole MF, et al: Core transcriptional regulatory circuitry in human embryonic stem cells. Cell 122: 947-956, 2005.
24. Tang Y, Kitisin K, Jogunoori W, et al: Progenitor/stem cells give rise to liver cancer due to aberrant TGF-beta and IL-6 signaling. Proc Natl Acad Sci USA 105: 2445-2450, 2008.
25. Lin YL, Han ZB, Xiong FY, et al: Malignant transformation of 293 cells induced by ectopic expression of human Nanog. Mol Cell Biochem 351: 109-116, 2011.
26. Lee TK, Castilho A, Cheung VC, Tang KH, Ma S and Ng IO: CD24(+) liver tumor-initiating cells drive self-renewal and tumor initiation through STAT3-mediated NANOG regulation. Cell Stem Cell 9: 50-63, 2011.
27. Shan J, Shen J, Liu L, et al: Nanog regulates self-renewal of cancer stem cells through the insulin-like growth factor pathway in human hepatocellular carcinoma. Hepatology 56: 1004-1014, 2012.
28. Xin H, Kong Y, Jiang X, et al: Multi-drug-resistant cells enriched from chronic myeloid leukemia cells by Doxorubicin possess tumor-initiating-cell properties. J Pharmacol Sci 122: 299-304, 2013.
29. Pérez-Tomás R: Multidrug resistance: retrospect and prospects in anti-cancer drug treatment. Curr Med Chem 13: 1859-1876, 2006.
30. Goda K, Bacsó Z and Szabó G: Multidrug resistance through the spectacle of P-glycoprotein. Curr Cancer Drug Targets 9: 281-297, 2009.
31. Lage H: MDR1/P-glycoprotein (ABCB1) as target for RNA interference-mediated reversal of multidrug resistance. Curr Drug Targets 7: 813-821, 2006.
32. He Y, Bi Y, Hua Y, et al: Ultrasound microbubble-mediated delivery of the siRNAs targeting MDR1 reduces drug resistance of yolk sac carcinoma L2 cells. J Exp Clin Cancer Res 30: 104, 2011.